| [1] |
Lammert F, Gurusamy K, Ko CW, et al.Gallstones[J].Nat Rev Dis Primers, 2016(2):16024.
|
| [2] |
Stinton LM, Myers RP, Shaffer EA.Epidemiology of gallstones[J].Gastroenterol Clin North Am, 2010, 39(2):157-169, vii.
|
| [3] |
Tsai CJ, Leitzmann MF, Willett WC, et al.Prospective study of abdominal adiposity and gallstone disease in US men[J].Am J Clin Nutr, 2004, 80(1):38-44.
|
| [4] |
Choi K, Amarasena T, Hughes A, et al.Management of bile duct stones at cholecystectomy: an Australian single-centre experience over 2 years[J].Surg Endosc, 2021, 35(3):1247-1253.
|
| [5] |
Wirth J, Joshi AD, Song M, et al.A healthy lifestyle pattern and the risk of symptomatic gallstone disease: results from 2 prospective cohort studies[J].Am J Clin Nutr, 2020, 112(3):586-594.
|
| [6] |
Portincasa P, Moschetta A, Palasciano G.Cholesterol gallstone disease[J].Lancet, 2006, 368(9531):230-239.
|
| [7] |
European Association for the Study of the Liver (EASL).EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones[J].J Hepatol, 2016, 65(1):146-181.
|
| [8] |
Criner GJ, Connett JE, Aaron SD, et al.Simvastatin for the prevention of exacerbations in moderate-to-severe COPD[J].N Engl J Med, 2014,370(23):2201-2210.
|
| [9] |
Saunders KD, Cates JA, Abedin MZ, et al.Lovastatin inhibits gallstone formation in the cholesterol-fed prairie dog[J].Ann Surg,1991, 214(2):149-154.
|
| [10] |
Duane WC, Hunninghake DB, Freeman ML, et al.Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile[J].Hepatology, 1988, 8(5):1147-1150.
|
| [11] |
Tazuma S, Kajiyama G, Mizuno T, et al.A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy[J].J Clin Gastroenterol, 1998, 26(4):287-291.
|
| [12] |
Boyko EJ.Observational research-opportunities and limitations[J].J Diabetes Complications, 2013, 27(6):642-648.
|
| [13] |
Katan MB.Apolipoprotein E isoforms, serum cholesterol, and cancer[J].Lancet, 1986, 1(8479):507-508.
|
| [14] |
Emdin CA, Khera AV, Kathiresan S.Mendelian randomization[J].JAMA, 2017, 318(19):1925-1926.
|
| [15] |
Hemani G, Zheng J, Elsworth B, et al.The MR-base platform supports systematic causal inference across the human phenome[J].Elife, 2018,7: e34408.
|
| [16] |
Li R, Huang G, Li Y, et al.Assessing the role of statin therapy in bladder cancer: evidence from a mendelian randomization study[J].Front Pharmacol, 2024, 15:1427318.
|
| [17] |
Min Y, Wei X, Liu Z, et al.Assessing the role of lipid-lowering therapy on multi-cancer prevention: a mendelian randomization study[J].Front Pharmacol, 2023, 14:1109580.
|
| [18] |
Li W, Ren A, Qin Q, et al.Causal associations between human gut microbiota and cholelithiasis: a mendelian randomization study[J].Front Cell Infect Microbiol, 2023, 13:1169119.
|
| [19] |
Burgess S, Butterworth A, Thompson SG.Mendelian randomization analysis with multiple genetic variants using summarized data[J].Genet Epidemiol, 2013, 37(7):658-665.
|
| [20] |
Bowden J, Davey Smith G, Haycock PC, et al.Consistent estimation in Mendelian randomization with some invalid instruments using a weighted Median estimator[J].Genet Epidemiol, 2016, 40(4):304-314.
|
| [21] |
Bowden J, Davey Smith G, Burgess S.Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression[J].Int J Epidemiol, 2015, 44(2):512-525.
|
| [22] |
Verbanck M, Chen CY, Neale B, et al.Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases[J].Nat Genet,2018, 50(5):693-698.
|
| [23] |
Smith GD, Ebrahim S.Mendelian randomization: prospects,potentials, and limitations[J].Int J Epidemiol, 2004, 33(1):30-42.
|
| [24] |
Burgess S, Davies NM, Thompson SG.Bias due to participant overlap in two-sample Mendelian randomization[J].Genet Epidemiol, 2016,40(7):597-608.
|
| [25] |
Smith JL, Roach PD, Wittenberg LN, et al.Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones[J].J Gastroenterol Hepatol,2000, 15(8):871-879.
|
| [26] |
Chapman BA, Burt MJ, Chisholm RJ, et al.Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor[J].Dig Dis Sci,1998, 43(2):349-353.
|
| [27] |
Tazuma S, Takizawa I, Kunita T, et al.Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia[J].Metabolism, 1995,44(11):1410-1412.
|
| [28] |
Mazzella G, Parini P, Festi D, et al.Effect of simvastatin,ursodeoxycholic acid and simvastatin plus ursodeoxycholic acid on biliary lipid secretion and cholic acid kinetics in nonfamilial hypercholesterolemia[J].Hepatology, 1992, 15(6):1072-1078.
|
| [29] |
Mitchell JC, Logan GM, Stone BG, et al.Effects of lovastatin on biliary lipid secretion and bile acid metabolism in humans[J].J Lipid Res, 1991, 32(1):71-78.
|
| [30] |
Hoogerbrugge-vd Linden N, de Rooy FW, Jansen H, et al.Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia[J].Gut, 1990, 31(3):348-350.
|
| [31] |
Abedin MZ, Narins SC, Park EH, et al.Lovastatin alters biliary lipid composition and dissolves gallstones: a long-term study in prairie dogs[J].Dig Dis Sci, 2002, 47(10):2192-2210.
|
| [32] |
Saunders KD, Cates JA, Abedin MZ, et al.Lovastatin and gallstone dissolution: a preliminary study[J].Surgery, 1993, 113(1):28-35.
|
| [33] |
Smit JW, van Erpecum KJ, Stolk MF, et al.Successful dissolution of cholesterol gallstone during treatment with pravastatin[J].Gastroenterology, 1992, 103(3):1068-1070.
|
| [34] |
Smit JW, van Erpecum KJ, Gadella MM, et al.Does the HMG-CoA reductase inhibitor pravastatin influence nucleation of cholesterol crystals in supersaturated model bile?[J].Eur J Gastroenterol Hepatol,1996, 8(3):197-200.
|
| [35] |
Miettinen TE, Vuoristo M.The sedimentable sterols in gallstone patients before and during ursodeoxycholic acid and simvastatin treatments[J].Scand J Gastroenterol, 1998, 33(12):1297-1302.
|
| [36] |
Erichsen R, Frøslev T, Lash TL, et al.Long-term statin use and the risk of gallstone disease: a population-based case-control study[J].Am J Epidemiol, 2011, 173(2):162-170.
|
| [37] |
Wang HH, Portincasa P, de Bari O, et al.Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol[J].Eur J Clin Invest, 2013, 43(4):413-426.
|
| [38] |
Chiu HF, Chen CC, Kuo HW, et al.Statin use and the risk of gallstone disease: a population-based case-control study[J].Expert Opin Drug Saf, 2012, 11(3):369-374.
|
| [39] |
Martin D, Schmidt R, Mortensen EM, et al.Association of statin therapy and risks of cholelithiasis, biliary tract diseases, and gallbladder procedures: retrospective cohort analysis of a US population[J].Ann Pharmacother, 2016, 50(3):161-171.
|
| [40] |
Shaffer EA.Gallstone disease: epidemiology of gallbladder stone disease[J].Best Pract Res Clin Gastroenterol, 2006, 20(6):981-996.
|
| [41] |
Ahmed MH, Hamad MA, Routh C, et al.Statins as potential treatment for cholesterol gallstones: an attempt to understand the underlying mechanism of actions[J].Expert Opin Pharmacother, 2011, 12(17):2673-2681.
|
| [42] |
Han T, Lv Y, Wang S, et al.PPARγ overexpression regulates cholesterol metabolism in human L02 hepatocytes[J].J Pharmacol Sci,2019, 139(1):1-8.
|
| [43] |
Bertolotti M, Gabbi C, Anzivino C, et al.Decreased hepatic expression of PPAR-gamma coactivator-1 in cholesterol cholelithiasis[J].Eur J Clin Invest, 2006, 36(3):170-175.
|
| [44] |
Smit JW, van Erpecum KJ, Portincasa P, et al.Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia[J].Gut, 1995, 37(5):654-659.
|
| [45] |
Porsch-Ozçürümez M, Hardt PD, Schnell-Kretschmer H, et al.Effects of fluvastatin on biliary lipids in subjects with an elevated cholesterol saturation index[J].Eur J Clin Pharmacol, 2001, 56(12):873-879.
|
| [46] |
Lanzarotto F, Panarotto B, Sorbara R, et al.Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid:evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans[J].Gut, 1999, 44(4):552-556.
|
| [47] |
Bodmer M, Brauchli YB, Krähenbühl S, et al.Statin use and risk of gallstone disease followed by cholecystectomy[J].JAMA, 2009,302(18):2001-2007.
|
| [48] |
Tsai CJ, Leitzmann MF, Willett WC, et al.Statin use and the risk of cholecystectomy in women[J].Gastroenterology, 2009, 136(5):1593-1600.
|
| [49] |
Pulkkinen J, Eskelinen M, Kiviniemi V, et al.Effect of statin use on outcome of symptomatic cholelithiasis: a case-control study[J].BMC Gastroenterol, 2014, 14:119.
|